The tumor HSP70 may combine with a variety of tumor antigen peptides
and present multiple antigen epitopes to T cells.
These include infusion of vaccines consisting of hapten-modified autologous melanoma cells, poorly characterized tumor lysates, peripheral blood mononuclear cells loaded with tumor antigen peptides
plus adjuvants, and the use of melanoma vaccines combined with therapies designed to eliminate pathways and signals that would down-regulate a protective immune response to the vaccine.
DCs are critical antigen-presenting cells (APC) which present antigen peptides
to T cells to initiate specific antitumor immune response.
In our experiments, the antitumor effect of mHSP/Ps was greater than that of any single HSP; HSP60 is a potent adjuvant that induces innate immune responses and has been used in vaccines as an effective adjuvant.[sup], Another major component, HSP110, was more effective than HSP70 in binding the peptide chain and can bind various peptides originating from HSP70 or Gp96.[sup] Our mixture of HSP/Ps included HSP60 and HSP110, in addition to HSP70 and Gp96, and could bind more antigen peptides
and potentially induce multifarious immune responses.